Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000939
Chunk: 11

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 11
---
organ Chase Bank, N.A., as depositary under the Deposit Agreement.

(q) “”
means The Depository Trust Company, or any successor performing substantially the same function for the Company.

(r) “” means Depositary Shares that are (i) issued in electronic form, (ii) the resale of which is registered under an effective
registration statement and (iii) timely credited, once a DWAC notice is received, by the Company to the Investor’s or its designee’s
specified Deposit/Withdrawal at Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer (FAST) Program, or any
similar program hereafter adopted by DTC performing substantially the same function.

| -3- |

(s) “” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

(t) “” means the issuance of (i) Depositary Shares, Ordinary Share Equivalents, options or other equity incentive awards
to employees, officers, directors or vendors of the Company pursuant to any equity incentive plan duly adopted for such purpose, by the
Company’s Board of Directors or a majority of the members of a committee of the Board of Directors established for such purpose,
(ii) any Securities issued to the Investor pursuant to this Agreement, (iii) any securities issued upon the exercise or exchange of or
conversion of any Depositary Shares or Ordinary Share Equivalents held by the Investor at any time, (iv) any securities issued upon the
exercise or exchange of or conversion of any Ordinary Share Equivalents that are issued and outstanding on the date of this Agreement,
provided that such securities referred to in this clause (iv) have not been amended since the date of this Agreement to increase the number
of such securities or to decrease the exercise price, exchange price or conversion price of such securities, (v) securities issued pursuant
to acquisitions, divestitures, licenses, partnerships, collaborations or strategic transactions approved by the Company’s Board
of Directors or a majority of the members of a committee of directors established for such purpose, (vi) Depositary Shares issued pursuant
to the Company’s employee share purchase plan or (vii) securities issued by the Company by any method deemed to be an “at
the market offering” as defined in Rule 415(a)(4) under the Securities Act, exclusively through a registered broker-dealer, as the
Company’s sales agent, pursuant to one or more written agreements between the Company and such